<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927120</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-17578</org_study_id>
    <secondary_id>NCI-2014-00755</secondary_id>
    <nct_id>NCT01927120</nct_id>
  </id_info>
  <brief_title>In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis</brief_title>
  <official_title>In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with
      Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus
      host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg
      differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence
      of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and
      mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and the
      polarization of emerging T helper cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2014</start_date>
  <completion_date type="Actual">March 9, 2017</completion_date>
  <primary_completion_date type="Actual">August 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regulatory T Cells (Tregs)/Total CD4+ Cells at Day 30 Post-HCT</measure>
    <time_frame>30 days post HCT</time_frame>
    <description>Percentage of Treg among blood CD4+ T cells at day 30 after hematopoietic cell transplantation (HCT), to compare to SIR/TAC alone data from a previous trial (median of 16%). The study was designed to capture an increase in regulatory T cells from a median of 16.0% at day +30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at Day +365</measure>
    <time_frame>365 days post HCT</time_frame>
    <description>Overall survival will be defined as the time from transplant date to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Relapse</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Incidence of primary disease relapse per standard definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Grade II-IV Acute GVHD by Day +100</measure>
    <time_frame>100 days post HCT</time_frame>
    <description>Acute GVHD will be graded per the 1995 consensus guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Chronic GVHD by Day +365</measure>
    <time_frame>365 days post HCT</time_frame>
    <description>Cumulative incidence of chronic GVHD by day +365 per NIH Consensus criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-relapse Death</measure>
    <time_frame>365 days post HCT</time_frame>
    <description>Incidence of Non-relapse death/Transplant-related mortality. Non-relapse death is defined as death in continuous remission from primary disease requiring transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Unexpected or Serious Adverse Events (AEs)</measure>
    <time_frame>Up to days 130 post HCT</time_frame>
    <description>Grade 3-5 unexpected or serious adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.03) were captured up to day +130 or 30 days after the last dose of IL-2. Events listed, with causality in relation to study treatment noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Treg Among Blood CD4+ T Cells at Day +90 After HCT</measure>
    <time_frame>90 days post HCT</time_frame>
    <description>The proportion of Tregs to non-Treg CD4+ cells to be assessed at day +90. Natural Killer Cells (NKs): Median K/uL NK cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 30</measure>
    <time_frame>30 days post HCT</time_frame>
    <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 90</measure>
    <time_frame>90 days post HCT</time_frame>
    <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +90.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Function of Blood Treg After Allogeneic HSCT</measure>
    <time_frame>30 days post HCT</time_frame>
    <description>Percent of Treg suppression at day +30. Investigators had also planned to test Treg function at day +90, if sufficient Tregs had been available for analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Natural Killer Cell (NK) Reconstitution</measure>
    <time_frame>365 days post HCT</time_frame>
    <description>Investigators planned to monitor natural killer cell (NK) reconstitution. Standard immune deficiency flow cytometry panels (IDP) was to be drawn on days +90, +180, and +365 to evaluate NK reconstitution. Results of standard lab tests to be compared to compiled data at a later date</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Graft-Versus-Host-Disease</condition>
  <arm_group>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <other_name>Proleukin®</other_name>
    <other_name>(aldesleukin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Orally on day -1. The dose for loading is 12 mg by mouth (PO)</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have an available 8/8 human leukocyte antigen (HLA)-A, -B, -C, and -DRB1
             matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell
             graft.

          -  Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid
             leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT.

               -  Acute Leukemia (AML or ALL) must be in complete remission defined as: &lt;5% marrow
                  blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow
                  &gt;20% cellular, and peripheral absolute neutrophil count &gt;1000/µL (platelet
                  recovery is not required).

               -  Myelodysplasia (MDS) and chronic myeloid leukemia (CML): Must have &lt;5% marrow
                  blasts.

               -  Myeloproliferative neoplasms (MPN): Must have &lt;5% peripheral / marrow blasts.

          -  Adequate vital organ function:

               1. Left ventricular ejection fraction (LVEF) ≥ 45% by multi gated acquisition (MUGA)
                  scan or ECHO

               2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and
                  adjusted diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on
                  pulmonary function tests

               3. Transaminases (AST, ALT) &lt; 2 times upper limit of normal values

               4. Creatinine clearance ≥ 50 cc/min.

          -  Performance status: Karnofsky Performance Status Score ≥ 80%

          -  Donor eligibility: Eligible donors will include healthy sibling, relative or unrelated
             donors that are matched with the patient at HLA-A, B, C, and DRB1 by high resolution
             typing.

        Exclusion Criteria:

          -  Active infection not controlled with appropriate antimicrobial therapy

          -  History of HIV, hepatitis B, or hepatitis C infection

          -  Anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered
             within 14 days before or planned to receive with HCT conditioning or as part of GVHD
             prophylaxis in the 14 days after HCT.

          -  Hypersensitivity to recombinant human IL-2

          -  Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-hodgkin lymphoma are excluded
             as these malignancies may express the IL-2 receptor and pose a potential growth signal
             to any present disease.

          -  Sorror's co-morbidity factors with total score &gt;4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Betts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <link>
    <url>http://www.haematologica.org/content/early/2017/01/19/haematol.2016.153072.long</url>
    <description>IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>June 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at Moffitt Cancer Center, April 2014 through December 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GVHD Regimen</title>
          <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants.</population>
      <group_list>
        <group group_id="B1">
          <title>GVHD Regimen</title>
          <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="22" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regulatory T Cells (Tregs)/Total CD4+ Cells at Day 30 Post-HCT</title>
        <description>Percentage of Treg among blood CD4+ T cells at day 30 after hematopoietic cell transplantation (HCT), to compare to SIR/TAC alone data from a previous trial (median of 16%). The study was designed to capture an increase in regulatory T cells from a median of 16.0% at day +30.</description>
        <time_frame>30 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Regulatory T Cells (Tregs)/Total CD4+ Cells at Day 30 Post-HCT</title>
          <description>Percentage of Treg among blood CD4+ T cells at day 30 after hematopoietic cell transplantation (HCT), to compare to SIR/TAC alone data from a previous trial (median of 16%). The study was designed to capture an increase in regulatory T cells from a median of 16.0% at day +30.</description>
          <population>All participants.</population>
          <units>percentage of CD4+Tregs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="12.8" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at Day +365</title>
        <description>Overall survival will be defined as the time from transplant date to death from any cause.</description>
        <time_frame>365 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at Day +365</title>
          <description>Overall survival will be defined as the time from transplant date to death from any cause.</description>
          <population>All participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="49.3" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Relapse</title>
        <description>Incidence of primary disease relapse per standard definitions.</description>
        <time_frame>1 year post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Relapse</title>
          <description>Incidence of primary disease relapse per standard definitions.</description>
          <population>All participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" lower_limit="9.2" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Grade II-IV Acute GVHD by Day +100</title>
        <description>Acute GVHD will be graded per the 1995 consensus guidelines.</description>
        <time_frame>100 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Grade II-IV Acute GVHD by Day +100</title>
          <description>Acute GVHD will be graded per the 1995 consensus guidelines.</description>
          <population>All participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="15.8" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Chronic GVHD by Day +365</title>
        <description>Cumulative incidence of chronic GVHD by day +365 per NIH Consensus criteria.</description>
        <time_frame>365 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Chronic GVHD by Day +365</title>
          <description>Cumulative incidence of chronic GVHD by day +365 per NIH Consensus criteria.</description>
          <population>All participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="36.1" upper_limit="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Non-relapse Death</title>
        <description>Incidence of Non-relapse death/Transplant-related mortality. Non-relapse death is defined as death in continuous remission from primary disease requiring transplantation.</description>
        <time_frame>365 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Non-relapse Death</title>
          <description>Incidence of Non-relapse death/Transplant-related mortality. Non-relapse death is defined as death in continuous remission from primary disease requiring transplantation.</description>
          <population>All participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Unexpected or Serious Adverse Events (AEs)</title>
        <description>Grade 3-5 unexpected or serious adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.03) were captured up to day +130 or 30 days after the last dose of IL-2. Events listed, with causality in relation to study treatment noted.</description>
        <time_frame>Up to days 130 post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Unexpected or Serious Adverse Events (AEs)</title>
          <description>Grade 3-5 unexpected or serious adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.03) were captured up to day +130 or 30 days after the last dose of IL-2. Events listed, with causality in relation to study treatment noted.</description>
          <population>All participants.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VOD, possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portal vein thrombosis, possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis, unlikely to be related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI bleed, unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute kidney injury, unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney stone, unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intracranial hemorrhage, unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Treg Among Blood CD4+ T Cells at Day +90 After HCT</title>
        <description>The proportion of Tregs to non-Treg CD4+ cells to be assessed at day +90. Natural Killer Cells (NKs): Median K/uL NK cells.</description>
        <time_frame>90 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Treg Among Blood CD4+ T Cells at Day +90 After HCT</title>
          <description>The proportion of Tregs to non-Treg CD4+ cells to be assessed at day +90. Natural Killer Cells (NKs): Median K/uL NK cells.</description>
          <population>All participants.</population>
          <units>K/uL NK cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.212" lower_limit="0.079" upper_limit="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 30</title>
        <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +30.</description>
        <time_frame>30 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 30</title>
          <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +30.</description>
          <population>All participants.</population>
          <units>percentage in total CD4s</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pSTAT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="10.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pSTAT5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="44" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pS6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="13.8" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 90</title>
        <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +90.</description>
        <time_frame>90 days post HCT</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>STAT3, STAT5 (Y694), and S6 Phosphorylation Among Treg and Non-Treg at Day 90</title>
          <description>Phosphorylation (p): pSTAT3, pSTAT5 (Y694), and pS6 among Treg and non-Treg at day +90.</description>
          <population>All participants.</population>
          <units>percentage in total CD4s</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pSTAT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="2.56" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pSTAT5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="33.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pS6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="0.91" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Function of Blood Treg After Allogeneic HSCT</title>
        <description>Percent of Treg suppression at day +30. Investigators had also planned to test Treg function at day +90, if sufficient Tregs had been available for analysis.</description>
        <time_frame>30 days post HCT</time_frame>
        <population>All evaluable participants at day +30.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Function of Blood Treg After Allogeneic HSCT</title>
          <description>Percent of Treg suppression at day +30. Investigators had also planned to test Treg function at day +90, if sufficient Tregs had been available for analysis.</description>
          <population>All evaluable participants at day +30.</population>
          <units>percentage of suppression</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Natural Killer Cell (NK) Reconstitution</title>
        <description>Investigators planned to monitor natural killer cell (NK) reconstitution. Standard immune deficiency flow cytometry panels (IDP) was to be drawn on days +90, +180, and +365 to evaluate NK reconstitution. Results of standard lab tests to be compared to compiled data at a later date</description>
        <time_frame>365 days post HCT</time_frame>
        <population>Lab test results to be compared to compiled data at a later date.</population>
        <group_list>
          <group group_id="O1">
            <title>GVHD Regimen</title>
            <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Natural Killer Cell (NK) Reconstitution</title>
          <description>Investigators planned to monitor natural killer cell (NK) reconstitution. Standard immune deficiency flow cytometry panels (IDP) was to be drawn on days +90, +180, and +365 to evaluate NK reconstitution. Results of standard lab tests to be compared to compiled data at a later date</description>
          <population>Lab test results to be compared to compiled data at a later date.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GVHD Regimen</title>
          <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, VOD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, staphylococcus epidermis bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cystitis non-infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, adenovirus cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, kidney stones</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Strategies to overcome interference from soluble IL-2 receptor and STAT3-mediated acute GVHD are needed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brian Betts</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-5410</phone>
      <email>brian.betts@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

